# Prince of Songkla University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/prince-of-songkla-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 76.5 |
| Citations | 1,191,227 |
| City | Songkhla |
| Country | TH |
| Description | Prince of Songkla University is a research organisation in Songkhla, TH. OpenAlex records 33,798 works and 1,191,227 citations for it. 11,179 researchers list it as their most recent affiliation. |
| Homepage | http://www.en.psu.ac.th/ |
| OpenAlex ID | https://openalex.org/I131868736 |
| Region | Songkhla |
| Researchers | 11,179 |
| ROR ID | https://ror.org/0575ycz84 |
| Type | education |
| Works | 33,798 |

## University papers

- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://scholariq.org/papers/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk/)
- [Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6](https://scholariq.org/papers/clinical-activity-of-afatinib-in-patients-with-advanced-non-small-cell-lung/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)

## University top topics

Showing 8 of 24.

- [Meat and Animal Product Quality](https://scholariq.org/topics/meat-and-animal-product-quality/)
- [Protein Hydrolysis and Bioactive Peptides](https://scholariq.org/topics/protein-hydrolysis-and-bioactive-peptides/)
- [Polymer Nanocomposites and Properties](https://scholariq.org/topics/polymer-nanocomposites-and-properties/)
- [Aquaculture Nutrition and Growth](https://scholariq.org/topics/aquaculture-nutrition-and-growth/)
- [biodegradable polymer synthesis and properties](https://scholariq.org/topics/biodegradable-polymer-synthesis-and-properties/)
- [Aquaculture disease management and microbiota](https://scholariq.org/topics/aquaculture-disease-management-and-microbiota/)
- [Nanocomposite Films for Food Packaging](https://scholariq.org/topics/nanocomposite-films-for-food-packaging/)
- [Biofuel production and bioconversion](https://scholariq.org/topics/biofuel-production-and-bioconversion/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.